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Abstract
A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-
release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical 
trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794, 
NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of 
glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of 
the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the 
infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated 
intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a 
radiosensitizing agent. Efficient transduction by RRV and expression of CD was confirmed in the 
highly aggressive, radioresistant human glioblastoma cell line U87-EGFRvIII and its parental cell 
line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after 
transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival 
assay and in vivo by bioluminescence imaging analysis. These results provide a convincing 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding Author: Noriyuki Kasahara, M.D., Ph.D. UCLA David Geffen School of Medicine 675 Charles E. Young Drive 
South, MRL-1551 Los Angeles, CA, 90095 Tel: 310-825-7112 FAX: 310-825-5204 nkasahara@mednet.ucla.edu.
**Current address: Departments of Cell Biology and Pathology, University of Miami, Florida, USA
Current address:
University of Miami Miller School of Medicine 1550 NW 10th Ave, Papanicolaou Bldg., Room 410 (M-877) Miami, FL, 33136 Tel: 
305-243-3243 FAX: 305-243-5885 nkasahara@med.miami.edu
CONFLICT OF INTEREST
HG, JR and DJ are employees and/or shareholders of Tocagen, Inc. NK is a consultant, has ownership interest, and is the recipient of a 
research grant from Tocagen, Inc. The research conducted under this grant award has been reviewed and approved by the UCLA 
Conflict of Interest Review Committee.
HHS Public Access
Author manuscript
Cancer Gene Ther. Author manuscript; available in PMC 2015 April 10.
Published in final edited form as:
Cancer Gene Ther. 2014 October ; 21(10): 405–410. doi:10.1038/cgt.2014.38.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-
selective replicative capability of RRV, and incorporation of radiation therapy into future clinical 
trials evaluating Toca 511 and Toca FC in brain tumor patients.
INTRODUCTION
Conventional replication-defective vectors, which are incapable of further propagation 
beyond initial infection, do not diffuse far from the injection site and therefore are 
inadequate for gene delivery into large solid tumors 1. Thus, the major obstacle has been the 
low efficiency of delivering prodrug activator genes to sufficient numbers of cancer cells in 
vivo using non-replicating vectors. To address such issues, we have developed retroviral 
replicating vectors (RRV), which we and others have shown in a variety of preclinical 
models to be capable of highly efficient gene delivery throughout solid tumor masses 
concomitant with viral replication 2-10. RRV-mediated gene delivery is tumor-selective in 
vivo because of the inability of RRV to infect non-dividing cells, and because anti-viral 
defense mechanisms active in normal cells are frequently mutated in cancer cells. We and 
others have confirmed that RRV are highly effective vectors for prodrug activator therapy in 
experimental models of glioma 7-13, and unlike oncolytic replicating viruses currently being 
tested in the clinic, RRV replication is intrinsically non-lytic and so the immunosuppressive 
tumor environment continues to shield the virus until extensive spread is attained, after 
which infected cells can be killed selectively and synchronously upon prodrug 
administration. Moreover, as the retrovirus integrates its transgene permanently into the 
cancer cell genome, residual infected glioma cells can become a reservoir for re-infection of 
malignant cells upon recurrence, enabling repeated cycles of prodrug administration to 
achieve further therapeutic benefit even after only a single injection of RRV 8, 12.
An improved version of one such RRV, Toca 511 (vocimagene amiretrorepvec), is currently 
being evaluated in multi-center Phase I dose-escalation trials for patients with recurrent 
high-grade glioma (www.clinicaltrials.gov, NCT01156584, NCT01470794, and 
NCT01985256). This vector delivers a human codon-optimized and thermo-stabilized 
version of the yeast cytosine deaminase (CD) prodrug activator gene 14. Its corresponding 
prodrug, 5-fluorocytosine (5-FC), is an orally-bioavailable FDA-approved anti-fungal agent 
that efficiently crosses the blood-brain barrier. The CD enzyme then converts 5-FC into 5-
fluorouracil (5-FU), which has a very short half-life and is therefore localized primarily 
within the RRV-infected tumor. Thus, the adverse effects of systemic 5-FU chemotherapy 
can be minimized, while still achieving very high local concentrations of 5-FU generated 
directly within the tumor. 5-FU, one of the most commonly used chemotherapeutic drugs, 
has been widely combined with radiation to obtain radiosensitization and synergistic killing 
in several human cancers 15.
Radiation is an important component of conventional first-line treatment of glioma and is 
used clinically for small recurrent gliomas, but to date, no studies have been reported 
evaluating RRV-mediated CD/5-FC prodrug activator gene therapy in combination with 
radiotherapy. Accordingly, here we investigated whether the high levels of intracellular 5-
FU generated by the clinical vector Toca 511 followed by a short pulse of 5-FC might exert 
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radiosensitizing effects on the human glioma cell line U87MG and its radio-resistant variant 
U87-EGFRvIII, both in cell culture as well as in a unique tumor establishment challenge 
model scored by bioluminescent imaging. Our results indicate that combining RRV-
mediated CD/5-FC prodrug activator gene therapy with radiation therapy can achieve even 
greater efficacy than either modality alone.
MATERIALS AND METHODS
Vectors
Plasmids encoding the RRV constructs pAC3-emd and pAC3-yCD2 (Toca 511) have been 
described previously 14. Both vectors are based on Moloney murine leukemia virus with an 
amphotropic envelope (4070A), and an internal ribosome entry site (IRES) linked to green 
fluorescent protein (emd) or an optimized yeast cytosine deaminase (yCD2), respectively, 
has been inserted into 3’-untranslated region of the viral genome (Fig. 1A, B). To produce 
AC3-emd virus, 293T cells were transiently transfected with pAC3-emd as previously 
described 3, 16. Supernatants were harvested and filtered 48 hours later, and stored at −80 °C. 
Preparations of AC3-yCD2 virus manufactured with the same process used for clinical 
vector production were provided by Tocagen Inc. Also, a self-inactivating (SIN) lentiviral 
vector expressing firefly luciferase (pRRL-sin-cPPT-hCMV-Fluc2) was provided from the 
UCLA Vector Core & Shared Resource Facility, and used in generating the luciferase-
marked glioblastoma cell lines used in this study. Firefly luciferase cDNA is inserted into 
the multiple cloning site of the vector. Lentiviral vector titers were determined by measuring 
viral p24 antigen concentration by ELISA as described previously 17.
Cell lines
The human glioma cell line U87EGFRvIII (18; generously provided by P. Mischel, UCSD) 
and parental cell line U87MG (U87; American Type Culture Collection (ATCC)# HTB-14) 
were maintained in exponential growth as monolayer cultures by serial passage at 37 °C / 
5% CO2, in Dulbecco'smodified Eagle'smedium (DMEM) with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin. To establish RRV-producing cell lines, 
U87EGFRvIII or U87 cells were infected with AC3-yCD2 or AC3-emd at a multiplicity of 
infection (MOI) of 0.1 and cultured for >30 days. To confirm presence of yeast CD gene in 
these stably transduced cell lines (U87-AC3-yCD2 and U87EGFRvIII-AC3-yCD2), 
quantitative real-time PCR analysis was performed as described previously 2, 19. For 
confirmation of GFP expression in U87-AC3-emd and U87EGFRvIII-AC3-emd, the GFP 
positive cell fraction was monitored at serial time points by flow cytometry (Beckman 
Coulter, CA, USA) 16. For in vivo bioluminescence imaging studies, U87EGFRvIII and 
U87EGFRvIII-AC3-yCD2 cells were transduced at a multiplicity of infection (MOI) of 2 
using lentiviral vector RRL-sin-cPPT-hCMV-Fluc2, and luciferase expression was 
confirmed by optical imaging (Xenogen IVIS, Alameda, CA, USA; Suppl. Fig. 1).
Western blot analysis
Total protein extracts were prepared from U87 and U87EGFRvIII cells infected with 
RRV(AC3-emd or AC3-yCD2) or uninfected, in RIPA buffer containing protease inhibitor 
(Sigma-Aldrich, St. Louis, MO, USA). Proteins contents were quantified using the Bradford 
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assay. Proteins (20 μg) were resolved in Laemmli buffer by SDS-PAGE and transferred to 
an Immobilon-P Transfer Membrane (Millipore, Billerica, MA, USA). Western blotting was 
performed using rabbit polyclonal anti-EGFR antibody (Millipore, Billerica, MA, USA) and 
rabbit polyclonal anti-beta actin antibody (Abcam, Cambridge, MA, USA). Membranes 
were treated with peroxidase-conjugated secondary antibodies (Bio-Rad Laboratories, 
Hercules, CA, USA) and analyzed with SuperSignal West Femto Chemiluminescent 
Substrate (Thermo Scientific, Fremont, CA, USA).
5-FC treatment
Stocks of 5-FC (Sigma-Aldrich, St. Louis, MO, USA) were stored at −70 °C. At the time of 
exposure, the cells were grown in T-75 flasks and harvested by removal of the growth 
medium and addition of 0.25 % trypsin. Cells were transiently exposed to 5-FC for 1 hour, 
based on their reported human circulating half-life values 20, 21, in 1.5 mL microfuge tubes 
at 37 °C, then suspended in fresh medium without 5-FC.
In vitro clonogenic assays
For drug dose-response experiments with or without irradiation, U87 cells received a 
transient pulse of drug treatment with 5-FC at different concentrations (0, 0.1, or 1 mM) for 
one hour. For irradiated groups, immediately after one-hour exposure, the cells were 
irradiated at the dose of 2 Gy or 4 Gy and re-plated at different dilutions in DMEM with 
10% FBS. The cells were incubated for 14 days at 37 °C, then fixed and stained. Only 
colonies with >50 cells were counted, and the clonogenic survival fraction was calculated by 
normalizing against the unirradiated control. A RS320 Irradiation System (Gulmay Medical, 
Bethel, CT, USA) was used with the following parameters: 300 kVp, HVL 3 mmCu, 10 mA, 
1.743 Gy / min at 34.7 cm FSD.
In vivo tumor establishment assay
Female Foxn1 nu/nu athymic mice (6~8 weeks old, Harlan Laboratories Inc.) were housed 
under specific pathogen-free conditions, and all animal studies were conducted under 
protocols approved by the UCLA Animal Research Committee. U87EGFRvIII-Fluc2 cells 
and U87EGFRvIII-AC3-yCD2-Fluc2 cells in culture were exposed to DMEM / 10% FBS 
with 0.1 mM 5-FC for two hours, and then replaced with fresh complete medium without 5-
FC. An aliquot of each cell line was irradiated with 2 Gy or 4 Gy, and remainder was 
unirradiated. Cell viability was then quantitated for each treatment group with trypan blue, 
and an equal number of viable cells was inoculated into the right cerebral hemisphere of 
athymic nude mice with a Hamilton syringe and stereotactic micro-injector (Narishige, 
Tokyo, Japan) (1 × 105 viable cells / 2 μl PBS). Injection site coordinates were 1 mm 
anterior and 1.5 mm lateral to the bregma and 3 mm deep from the dura mater. Luciferase 
signals from brain tumors were examined by optical in vivo imaging every 3 or 4 days until 
one mouse in each group died due to tumor progression. Bioluminescence data was analyzed 
by Living Image™ Software (Xenogen IVIS, Alameda, CA, USA).
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Statistical analysis
For in vitro survival data, Two-Way ANOVA was performed for statistical comparison of 
the radiosensitivity between groups, and p values < 0.05 were considered significant. For in 
vivo data, ANOVA was performed for statistical comparison of bioluminescence signals 
between groups, and p values < 0.05 were considered significant. All analysis were 
performed using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA).
RESULTS
RRV transduction does not affect the EGFR expression status of U87EGFRvIII cells
The parental U87 glioblastoma cell line expresses low levels of wild-type epidermal growth 
factor receptor (EGFR), and does not express the EGFR variant vIII (EGFRvIII). 
Overexpression of EGFRvIII in this cell line results in a highly aggressive and radioresistant 
phenotype 18, 22, 23 . Therefore, we first sought to determine whether the radiation sensitivity 
of these glioma cells might be affected by RRV transduction per se. To this end, we 
examined the expression levels of EGFRvIII protein before and after transduction with RRV 
in both parental U87 cells and U87EGFRvIII cells. Both cell lines were inoculated with 
AC3-yCD2 or AC3-emd (Fig. 1A & 1B, respectively) at an MOI of 0.1 and cultured for 30 
days to allow adequate time for viral spread throughout the culture, confirming stable 
transduction by flow cytometry for AC3-emd or quantitative real-time PCR for AC3-yCD2 
(data not shown). Western blot analysis of total protein extracts from both cell lines, with or 
without RRV transduction, confirmed that EGFR protein was detected in U87EGFRvIII 
cells but not in parental U87 cells, and transduction with AC3-emd or AC3-yCD2 did not 
detectably alter EFRvIII expression status in either cell line (Fig. 1C).
Highly effective radiosensitization of AC3-yCD2 (Toca 511) transduced cells with a single 
short exposure to 5-FC prodrug
We evaluated whether RRV-mediated transduction of the CD gene would change the 
radiosensitivity of U87 cells after exposure to a short pulse of high-concentration 5-FC in 
vitro. Clonogenic survival curves were generated of U87 and U87-AC3-yCD2 cells, without 
or with exposure to 5-FC (0.1 or 1 mM) for 1 hour, immediately prior to irradiation at 2 Gy 
or 4 Gy, and normalized against their respective controls (unirradiated group) (Fig. 2). As 
expected, the survival curves for transduced or untransduced U87 cells without 5-FC 
exposure were not significantly different (p=0.1226). However, cells that have been 
transduced with RRV expressing the CD gene showed reduced clonogenic survival after the 
transient exposure to 5-FC at 0.1 mM or 1 mM concentration compared to the control group 
at any radiation dose tested. Two-way ANOVA revealed that the effect of 5-FC 
concentration and radiation dose both affected the results significantly (p value = 0.0121 and 
< 0.0001, respectively).
Radiosensitization effect of CD prodrug activator gene transduction with 5-FC pulse 
confirmed in vivo by intracranial tumor establishment assay
To next evaluate whether combining CD/5-FC prodrug activator gene therapy with 
irradiation would exert an enhanced cytotoxic effect in vivo, we used a radioresistant U87 
Takahashi et al. Page 5
Cancer Gene Ther. Author manuscript; available in PMC 2015 April 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
subline, U87EGFRvIII, and devised an intracranial tumor establishment assay that employs 
glioma cell lines expressing the firefly luciferase reporter gene, which provides a 
quantitative bioluminescence readout that can be monitored in real-time by non-invasive 
optical imaging. Transduction with a conventional replication-defective lentiviral vector 
expressing luciferase resulted in a comparable level of bioluminescence from both 
U87EGFRvIII-FLuc2 and U87EGFRvIII-AC3-yCD2-FLuc2 cells upon exposure to 
luciferin, and a highly robust quantitative correlation between cell number and 
bioluminescent signal intensity was confirmed for both cell lines by optical imaging in vitro 
(Supplementary Fig. 1).
Prior to tumor establishment and optical imaging analysis in vivo, radiosensitization 
procedures were performed ex vivo, enabling precise control over prodrug concentration, 
exposure time, and radiation dose. Accordingly, U87EGFRvIII-Fluc2 or U87EGFRvIII-
AC3-yCD2-Fluc2 cells in culture were first exposed for 2 hours to 0.1 mM 5-FC, which 
approximates the lowest 5-FC concentration measured in cerebrospinal fluid from patients 
undergoing treatment for CNS fungal infection 24. After this short pulse of 5-FC followed 
by washout, aliquots from each cell culture were given either 2 Gy or 4 Gy irradiation, and 
the remaining cells served as unirradiated controls. After stereotactic implantation into 
athymic mouse brain (1 × 105 cells / mouse), bioluminescence signals during tumor 
establishment and progression were monitored by in vivo optical imaging at serial time 
points (Fig. 3A and 3B).
Initial bioluminescence signal intensities of uninfected U87EGFRvIII-FLuc2 cells without 
irradiation, or with either 2 Gy or 4 Gy irradiation, were all closely clustered together at the 
first time point (Day 4), indicating that there were no significant disparities in the implanted 
cell dose among these groups. Among these groups, there was some reduction in 
bioluminescence signal intensity from tumors established with irradiated uninfected cells as 
compared to unirradiated control tumors at the next time point (Day 7), however, 
bioluminescence signals in all of these groups continued to increase thereafter, indicating 
progressive tumor growth. By the third time point (Day 10), all of the uninfected 
U87EGFRvIIIFluc2 tumor groups showed high signal intensities, and there were no 
significant differences between them. This is consistent with previous reports characterizing 
U87EGFRvIII cells which have been reported to form radioresistant and aggressive tumors, 
and indeed, imaging could not be performed beyond Day 10 due to symptoms of tumor 
progression necessitating animal termination, as expected from the shorter survival time of 
controls implanted with intracerebral U87EGFRvIII tumors as compared to parental U87 
tumors (Supplementary Fig. 2).
Similarly, initial bioluminescence signal intensities of infected U87EGFRvIII-AC3-yCD2-
Fluc2 cells, either without irradiation or with 2 Gy or 4 Gy irradiation, were all closely 
clustered together at the first time point (Day 4), again indicating that there were no 
significant disparities in the implanted cell dose among these groups. However, all three of 
these infected U87EGFRvIII-AC3-yCD2-Fluc2 tumor groups, whether unirradiated or 
irradiated, showed significantly reduced signal intensities compared to the uninfected 
U87EGFRvIII-FLuc2 tumor groups (Fig. 3B, p < 0.05), even though the same number of 
viable cells had been inoculated intracerebrally on Day 0 for all groups, suggesting that even 
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a short pulse of 5-FC prodrug had significantly impacted the post-implantation viability or 
growth rate of infected glioma cells expressing yCD2, regardless of irradiation. 
Subsequently, bioluminescence from animals implanted with infected U87EGFRvIII-AC3-
yCD2-Fluc2 cells exposed to 5-FC but without irradiation showed increasing signal 
intensities after Day 7, indicating tumor progression. In contrast, bioluminescence after Day 
7 was consistently lower in infected U87EGFRvIII-AC3-yCD2-Fluc2 groups with 5-FC and 
either 2 Gy or 4 Gy irradiation as compared to unirradiated infected controls, and these 
statistically significant reductions in signal intensities of the irradiated groups continued 
through Day 17 (Fig. 3B, p < 0.001), when the unirradiated infected control animals had to 
be terminated. Taken together with the relative lack of tumor growth inhibition in uninfected 
irradiated groups, this indicates a potent radiosensitization effect of yCD2 / 5-FC prodrug 
activator gene therapy, even when pre-implantation exposure was limited to a lower 
concentration of 5-FC for only 2 hours prior to irradiation.
DISCUSSION
AC3-yCD2 represents an improved RRV exhibiting enhanced genomic stability during 
serial replication, and with enhanced potency due to the use of yeast CD rather than bacterial 
CD25, and extensive sequence modifications for codon optimization and thermostabilization 
at mammalian body temperature 14. As noted, AC3-yCD2 (Toca 511) in combination with 
Toca FC is being evaluated in clinical trials in patients with recurrent high-grade glioma 
(www.clinicaltrials.gov: NCT01156584, NCT01470794, and NCT01985256). To investigate 
if concomitant radiation therapy would be compatible with this approach and enhance 
glioma cell killing, in the present study we evaluated whether 5-FC would radiosensitize 
glioma cells that are infected by AC3-yCD2, while sparing uninfected cells.
In clonogenic survival assays, we found that 1 hour of exposure to 5-FC resulted in 
considerably enhanced killing of U87 glioma cells infected with AC3-yCD2 after 
irradiation, and this effect was more apparent at the lower radiation dose. The data therefore 
suggest that rapid and efficient conversion of 5-FC to 5-FU intracellularly even after a 
relatively short pulse of 5-FC in an infected tumor would be sufficient to achieve a 
significant radiosensitization effect.
To evaluate the effects of prior ex vivo exposure to prodrug and/or radiation, we employed a 
novel bioluminescence optical imaging-based method for non-invasive in vivo monitoring. 
Performing these treatments ex vivo enabled precise control over dosage and timing of 
exposure, while bioluminescence imaging provided a quantitative, consistent, and 
reproducible readout in vivo. Using this assay, AC3-yCD2 & 5-FC-mediated 
radiosensitization was confirmed to significantly impact subsequent establishment of 
radioresistant U87EGFRvIII tumors in vivo, even with transient pulse of 5-FC.
After a single pulse of 5-FC prodrug for 2 hours, RRV-transduced U87EGFRvIII-AC3-
yCD2-Fluc2 cells showed significantly reduced bioluminescent tumor signals as compared 
to untransduced U87EGFRvIII-Fluc2 cells even at the first imaging time point (Day 4), even 
though the number of injected viable cells on Day 0 had been equal (1 × 105 cells). This 
indicates that, even within 2 hours, the cytotoxic effects of prodrug uptake and conversion in 
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the infected cells was sufficient to cause eventual lethality in a majority of these cells (~90% 
based on bioluminescence signal quantitation, see Fig. 3B), when the cells attempted to 
divide after implantation in vivo.
Furthermore, while bioluminescence imaging showed comparable signal intensity from 
unirradiated and irradiated groups at the first imaging time point, indicating that there was 
no significant difference in initial tumor establishment among these groups, subsequent 
tumor growth was significantly delayed in the RRV-transduced groups that were also 
irradiated following the short pulse of 5-FC prodrug. This suggests that even short-term 
exposure of glioma cells expressing yCD2 to 5-FC prodrug may have contributed to 
blocking these cells from radiation-induced Potentially Lethal Damage Repair, thereby 
significantly impacting their post-implantation survival or proliferation rate.
It should also be noted that only a single dose of prodrug was used in the present study, and 
while this was found to be sufficient to mediate both transient tumor growth inhibition and 
radiosensitization effects, longer-term survival has been achieved by repeated prodrug 
administration in intracranial glioma models. Accordingly, multiple cycles of 5-FC prodrug 
administration are employed in current clinical protocols, and this may provide on-going 
sensitization effects for multiple fractionated doses of radiation as well. These encouraging 
results therefore support the evaluation of a combined treatment regimen incorporating 
radiation therapy into future clinical trials employing AC3-yCD2 (Toca 511) and Toca FC in 
patients with gliomas. Unlike radiosensitizing agents which are systemically active, the local 
production and action of 5-FU by RRV-mediated CD / 5-FC prodrug activator therapy 
should allow for radiation synergy selectively in the tumor, while sparing nearby healthy 
tissues.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A, B: Design of retroviral replicating vectors AC3-yCD2 (Toca 511) (A) and AC3-emd (B). 
Both vectors are derived from amphotropic (4070A) MLV, in which an IRES-yCD2 or 
IRES-GFP cassette has been inserted downstream of the envelope sequence. CMV, 
cytomegalovirus promoter; U3/R/U5, domains of viral long terminal repeat; ψ, packaging 
signal; gag/pol/4070A env, viral coding sequences. C, EGFR protein expression in U87 and 
U87EGFRvIII cells, with and without AC3-emd or AC3-yCD2 transduction. Upper panel: 
Total protein extracts from cells stably transduced with either RRV and from uninfected 
control cells were analyzed by Western blot with anti-EGFR antibody (Millipore, Billerica, 
MA, USA). Lower panel: β-actin antibody (Abcam, Cambridge, MA, USA) was used as an 
internal loading control.
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Figure 2. 
In vitro clonogenic survival fractions of U87 and U87-AC3-yCD2 cells with or without 
short exposure to 5-FC at different concentrations. In order to investigate the 
radiosensitization activity of 5-FU, which was intracellulary converted from 5-FC, the cells 
were pulsed with 5-FC (0.1 mM or 1 mM) for 1 hour, then followed by 2 Gy or 4 Gy 
irradiation. Control cells were not irradiated in each group. After 14 days, colonies were 
fixed, stained and counted. Each point represents the average of three replicates, bars 
indicate SD, NS: not significant, *: p < 0.05, ***: p < 0.001.
Takahashi et al. Page 12
Cancer Gene Ther. Author manuscript; available in PMC 2015 April 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
Brain tumor establishment and growth in vivo monitored by bioluminescence optical 
imaging after intracerebral implantation of glioma cells exposed to prodrug pulse and 
irradiation ex vivo. Uninfected and AC3-yCD2-infected U87EGFRvIII human glioma cells 
were pulsed with 0.1 mM 5-FC for 2 hours ex vivo, then unirradiated or irradiated with 2 Gy 
or 4 Gy, prior to stereotactic intracerebral implantation in athymic nude mice on Day 0 (1 × 
105 cells / mouse). Bioluminescence signals from brain tumors were monitored every 3 or 4 
days by in vivo optical imaging until one mouse in each group died due to tumor 
progression. A: Representative bioluminescence images of established brain tumors for each 
group on days 4, 7, 10, 14 and 17 are paneled. Mice implanted with the cells infected with 
RRV and irradiated at 2 Gy or 4 Gy showed marked tumor growth inhibition compared to 
other groups. B: Average signal intensities in each group were plotted; bars indicate SD. 
NS: not significant, *: p < 0.05, ***: p < 0.001.
RRV(−): U87EGFRvIII-Fluc2 cells without irradiation, represented as white circles (○)
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RRV(+): U87EGFRvIII-AC3-yCD2-Fluc2 cells without irradiation, black circles (●)
RRV(−) 2Gy: U87EGFRvIII-Fluc2 cells irradiated with 2 Gy, white rectangles (□)
RRV(+) 2Gy: U87EGFRvIII-AC3-yCD2-Fluc2 cells irradiated with 2 Gy, black rectangles 
(■);
RRV(−) 4Gy: U87EGFRvIII-Fluc2 cells irradiated with 4 Gy, white triangles (Δ)
RRV(+) 4Gy: U87EGFRvIII-AC3-yCD2-Fluc2 cells irradiated with 4 Gy, black triangles 
(▲).
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